Linagliptin

Active ingredient: Linagliptin

In short: Linagliptin tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Limitations of Use Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in t

Forms & strengthsLinagliptin 5 mg tablets are white or off-white, round, biconvex, film-coated tablets with “S75” debossed on one side and blank on the other side.
LabelSunshine Lake Pharma Co., Ltd.
Label updatedJan 16, 2026

What is Linagliptin used for?

Linagliptin

tablet is indicated as an adjunct to diet and exercise to improve

glycemic control in adults with type 2 diabetes mellitus

.

Limitations of Use

Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.

Linagliptin has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using linagliptin

.

Linagliptin dosage

The recommended dose of linagliptin is 5 mg

once daily.

Linagliptin tablets can

be taken with or without food.

How to take Linagliptin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Pancreatitis

Inform patients that acute pancreatitis

has been reported during use of linagliptin. Inform patients

that persistent severe abdominal pain, sometimes radiating to the

back, which may or may not be accompanied by vomiting, is the hallmark

symptom of acute pancreatitis. Instruct patients to discontinue linagliptin

promptly and contact their physician if persistent severe abdominal

pain occurs .

Heart Failure

Inform patients of the signs and symptoms of heart failure. Before initiating linagliptin, patients should be asked about a history of heart failure or other risk factors for heart failure including moderate to severe renal impairment. Instruct patients to contact their healthcare provider as soon as possible if they experience symptoms of heart failure, including increasing shortness of breath, rapid increase in weight or swelling of the feet .

Hypoglycemia

Inform patients that the incidence of hypoglycemia

is increased when linagliptin is added to a sulfonylurea or insulin

and that a lower dose of the sulfonylurea or insulin may be required

to reduce the risk of hypoglycemia

. …

Warnings & precautions

Do not take this medicine if: Linagliptin is contraindicated in patients with

a history of a hypersensitivity reaction to linagliptin, such as anaphylaxis,

angioedema, exfoliative skin conditions, urticaria, or bronchial Linagliptin is contraindicated in patients with hypersensitivity to linagliptin or any of the excipients in linagliptin tablets, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred

.

Acute pancreatitis, including fatal pancreatitis, has been reported in patients treated with linagliptin.

Take careful notice of potential signs and symptoms

of pancreatitis. If pancreatitis is suspected, promptly discontinue

linagliptin and initiate appropriate management. It is unknown whether

patients with a history of pancreatitis are at increased risk for

the development of pancreatitis while using linagliptin.

An association between DPP-4 inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class. These trials evaluated patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease.

Consider the risks and benefits of linagliptin prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy. Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of linagliptin.

Insulin secretagogues and insulin are known to cause hypoglycemia. …

Linagliptin side effects

The following serious adverse reactions are described below or elsewhere in the prescribing information:

Pancreatitis

Heart Failure

Use with Medications Known to Cause Hypoglycemia

Hypersensitivity Reactions

Severe and Disabling Arthralgia

Bullous Pemphigoid

Because clinical

trials are conducted under widely varying conditions, adverse reaction

rates observed in the clinical trials of a drug cannot be directly

compared to rates in the clinical trials of another drug and may not

reflect the rates observed in practice.

The safety evaluation of linagliptin 5 mg once daily in

patients with type 2 diabetes is based on 14 placebo-controlled trials, 1 active-controlled study, and one study in patients with severe renal impairment. In the 14 placebo-controlled studies, a total of 3625

patients were randomized and treated with linagliptin 5 mg daily and

2176 with placebo. The mean exposure in patients treated with linagliptin

across studies was 29.6 weeks. The maximum follow-up was 78 weeks.

Linagliptin 5 mg once daily was studied as

monotherapy in three placebo-controlled trials of 18 and 24 weeks’

duration and in five additional placebo-controlled studies lasting

≤18 weeks. …

Drug interactions

Rifampin

decreased linagliptin exposure, suggesting that the efficacy of linagliptin

may be reduced when administered in combination with a strong P-gp

or CYP3A4 inducer. Therefore, use of alternative treatments is strongly

recommended when linagliptin is to be administered with a strong P-gp

or CYP3A4 inducer

.

Coadministration of linagliptin with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia

.

About this medicine

Linagliptin tablets contain,

as the active ingredient, an orally-active inhibitor of the dipeptidyl

peptidase-4 (DPP-4) enzyme.

Linagliptin

is described chemically as 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-

The empirical formula is C

25H

28N

8O

2 and the molecular weight is 472.54 g/mol. The structural formula

is:

Linagliptin is a white to yellowish, not or only slightly hygroscopic

solid substance. It is very slightly soluble in water (0.9 mg/mL).

Linagliptin is soluble in methanol (ca. 60 mg/mL), sparingly soluble

in ethanol (ca. 10 mg/mL), very slightly soluble in isopropanol (<1

mg/mL), and very slightly soluble in acetone (ca. 1 mg/mL).

Each film-coated tablet of linagliptin contains

5 mg of linagliptin free base and the following inactive ingredients:

mannitol, pregelatinized starch, copovidone, and magnesium

stearate. In addition, the film coating contains the following inactive

ingredients: hypromellose, titanium dioxide and polyethylene glycol. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID cbdbd4b2-c07b-00e1-e053-2995a90a5fc9. Read the full official label on DailyMed.

Related medicines

Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro